Summary Hypoxia was assessed in three murine tumour models in vivo by measuring the incorporation of 7-(4'-(2-nitroimidazole-1-yl)-butyl)-theophylline (NITP), an immunologically identifiable hypoxia marker that binds bioreductively to cells under low-oxygen conditions. Proliferating cells were labelled in the same tumours by administering the thymidine analogue bromodeoxyuridine (BrdUrd). The relative hypoxia in each cell cycle phase of cells isolated from tumours was assessed by addition of propidium iodide with analysis by flow cytometry. There was no relationship between tumour volume and hypoxia in either the anaplastic sarcoma SaF or the poorly differentiated carcinoma CaNT and only a slight negative correlation in moderately well-differentiated carcinoma Rh. The G1/Go phase contained the greatest number of aneuploid hypoxic cells (aneuploid hypoxia ranging from less than 1% up to 40%, 38% and 71% in SaF, CaNT and Rh respectively), although there were significant amounts of hypoxia present in S-and G/M phases for all three tumours examined. However, the highest proportion of hypoxia occurred in the G/M phase, in which up to 60% of the cells were hypoxic. Simultaneous measurement of hypoxia, proliferation and DNA content using a novel triple-staining flow cytometry method showed that hypoxic cells could actively participate in the cell cycle. In addition, the cell cycle distribution of NITP and BrdUrd labelling showed that hypoxic cells could progress through the cell cycle, although their rate of progression was slower than that of better oxygenated cells.
Hypoxic radioresistant regions in some tumours are thought to reduce the efficacy of curative radiotherapy, and the sparing effect of proliferation of tumour cells during a course of conventional fractionated radiotherapy can be equivalent to several fractions of radiation. Proliferation can be studied by incorporation of the thymidine analogues bromo-and iododeoxyuridine, which can be identified using a monoclonal antibody with either flow cytometry analysis or immunohistochemical end points Wilson et al, 1985) . Measurements of potential doubling time (Tpot) are currently being undertaken in a series of trials comparing conventional with accelerated fractionation, and some show good evidence that pretreatment cell kinetics can predict treatment outcome (Wilson et al, 1988; Begg et al, 1992 ; Corvo et al, 1995) . The degree of hypoxia within a solid tumour is important as hypoxic cells will be up to three times more resistant to radiotherapy than their better oxygenated counterparts (Gray et al, 1953) . Meta-analysis of hypoxia-directed treatments has shown that regimens counteracting hypoxia in tumours are beneficial to patient survival, particularly in head and neck cancer (Overgaard, 1992) . However, before further data can be obtained to support this conclusion, a reliable method of measuring clinical tumour hypoxia before treatment must be found. Several techniques are being developed and have progressed to clinical trial (Stone et al, 1993) , with the Eppendorf oxygen microelectrode currently being the method of choice.
Despite numerous studies of proliferation and hypoxia in tumours as individual factors affecting treatment outcome, there has been little investigation of these parameters in combination. The greater proportion of previous work investigated the cell cycle progress of cells in vitro subjected to extremes of hypoxia (Pettersen and Lindmo, 1983; Shrieve and Begg, 1985; Amellen and Pettersen, 1991) , but few have attempted to study their interaction in vivo. Zeman et al (1993) found that in sequential histological sections-of canine tumours there was no systematic relationship between hypoxia and proliferating cell nuclear antigen markers. However, clusters of proliferating cells were reported distal to blood vessels. In a small series of clinical softtissue sarcomas, Nordsmark et al (1996) reported that the fastest proliferating cells were found in the most hypoxic tumours (characterized by median pO2), although there was no correlation with hypoxic fraction. Hypoxic sarcomas are also more likely to metastasize than better oxygenated tumours (Brizel et al, 1996) . Hypoxic cells accumulate wild-type p53 (Graeber et al, 1994) , which is required for efficient induction of apoptosis by hypoxia (Graeber et al, 1996) . However, this mechanism also provides a selective pressure for outgrowth of cell lineages with mutated or deleted p53 in tumours, suggesting that hypoxia may ultimately select for a more aggressive phenotype.
We have measured hypoxia using bioreductive binding of NITP, which consists of a 2-nitroimidazole with an immunologically recognizable theophylline sidechain. The 2-nitroimidazole component binds to cellular macromolecules under low-oxygen conditions, and the bound adducts of the probe, in hypoxic cells, can then be identified and quantified by antibodies raised against the theophylline (Hodgkiss et al, 1991) . S-phase tumour cells, actively synthesizing DNA in the cell cycle, can be labelled by their incorporation of the DNA content .. Figure 1 Typical flow cytometry profiles of cell nuclei prepared from SaF, CaNT and Rh murine tumours 2 h after treatment with NITP and BrdUrd in vivo and stained for hypoxia (bound NITP metabolites), proliferation (BrdUrd incorporation) and DNA content of cell nuclei, with simultaneous analysis of all three parameters in the SaF and CaNT tumours using three-colour flow cytometry. The regions on the SaF bivariate distributions represent the following cell populations: Rl, hypoxic; R2, normoxic; R3, BrdUrd-labelled; R4, BrdUrd-unlabelled. Markers set on the SaF DNA histogram represent; Ml, diploid host cells; M2, aneuploid tumour cells; M3, Gl; M4, S; M5, G/M DNA precursor bromodeoxyuridine (BrdUrd). We have developed a novel three-colour staining flow cytometry method to measure the BrdUrd, NITP and DNA content of tumour cells, so that the interaction of these three parameters can be investigated (Webster et al, 1995) . In this paper, we describe the cell cycle distribution of hypoxia in three murine tumour models by flow cytometry and follow the progress of hypoxic cells through the cell cycle by simultaneous evaluation of hypoxia (NITP), proliferation (BrdUrd) and DNA content.
MATERIALS AND METHODS

Mouse tumour models
The three tumours studied arose spontaneously in the Gray Laboratory animal colony (Hewitt and Wilson, 1961; Hewitt et al, 1973; Denekamp et al, 1980 
Hypoxia staining for flow cytometry
The method has been reported previously (Hodgkiss et al, 1991) . Briefly, 106 ethanol-fixed cells were centrifuged in 5 ml of PBS at 2000 r.p.m. for 5 min and resuspended in neat rabbit antiserum to theophylline (Sigma, Dorset, UK) for 1 h. The cells were washed with 5 ml of PBS and resuspended in 0.25 ml of PBS containing 0.5%. Tween 20 and 0. 1% normal goat serum (PNT) with 25 pl of IgG fluorescein isothiocyanate-conjugated goat anti-rabbit antiserum (Sigma) for 1 h. Cells were washed in 5 ml of PBS and the pellet resuspended in 2 ml of PBS containing 1 mg ml-' RNAase and 10 jug ml-' propidium iodide. The method for simultaneous measurement of hypoxia proliferation and DNA content has been reported previously (Webster et al, 1995) . Briefly, 106 ethanol-fixed cells were washed in PBS, centrifuged for 5 min at 2000 r.p.m. and the pellet resuspended in 0.2 mg ml' pepsin in 2 M hydrochloric acid for 20 min at room temperature. The resultant nuclei were washed twice in PBS and re-suspended in 100 g1 of PNT containing 5 p1 of mouse monoclonal to BrdUrd (Dako, Bucks, UK). After 1 h incubation, the nuclei were washed and the pellet resuspended in 100 gl of PNT with 25 p1 of R-phycoerythrin-conjugated anti-mouse lgG (Dako) for a further hour. After washing, the pellet was resuspended in 250 pl of undiluted rabbit anti-theophylline antiserum for 1 h. The final antibody solution, 250 pl of PNT with 25 pl of anti-rabbit IgG FITC conjugate, was added after a further wash and also incubated British Journal of Cancer (1998) 77(2) Using the regions shown in Figure 1 , total hypoxia (RI) including both diploid and aneuploid cells can be calculated. Diploid and aneuploid hypoxia were estimated from a DNA histogram gated on RI, with markers (MI and M2 respectively) set for the appropriate populations. The results for total, aneuploid and diploid hypoxia for SaF, CaNT and Rh tumours are shown in Table 1 . There is a wide inter-and intra-tumour variation in aneuploid hypoxia with all three tumour types. The diploid population of cells, consisting of macrophages, lymphocytes and stromal cells, also showed hypoxia but to a lesser extent than the aneuploid population, and the mean fluorescence of the diploid population was lower than that of the aneuploid cells. This was especially noticeable in the diploid G2IM population amid the aneuploid S-phase cells of the Rh tumour (Figure 1) . Figure 2 shows the relationship between aneuploid hypoxia and tumour volume. At these macroscopic sizes, there was no correlation between volume and hypoxia in the Saf and CaNT tumours (Spearman's correlation coefficient rho = 0.139, P = 0.465 and -0.0186, P = 0.925), respectively, while the Rh tumour showed a slight trend that was just significant (rho = -0.385, P = 0.0432) for hypoxia to fall with increasing volume.
Cell cycle distribution of hypoxia
Analysis of the distribution of hypoxia within the cell cycle was carried out by setting markers (M2 to M5) on DNA histograms gated on the hypoxic and oxic cells (Figure 1) . Hypoxia was present throughout the cell cycle ( Figure 3 and Table 2 ), and the G1/Go phase contained the greatest number of hypoxic cells and was significantly different from the S-and G2 phases (Table 2 ). In the SaF GI/Go hypoxia ranged from < 1% to 24% in the CaNT from < 1% to 23% and in the Rh from < 1% to 58% of the aneuploid hypoxic population. This is not surprising as, in all three tumours, GI/Go represents 40% of the total cell population. In all three tumour types, when hypoxia was present, S-and G2/M phases also contained significant numbers of hypoxic cells.
However, calculation of the proportion of hypoxic cells within each individual phase of the cell cycle showed that, although the greatest number of hypoxic cells resided in G1/Go, the phase of the cell cycle with the highest proportion of hypoxia was G/M ( Figure 4 and Table 3), with typically a two-fold lower proportion of hypoxic cells within the GJG, and S-phases. This effect was most marked in the SaF tumour, but similar patterns were also seen in the CaNT and Rh tumours, and in each case G2was significantly different from the G, and S-phases (Table 3) .
Cell progression studies Analysis of cell progression in CaNT and SaF tumours labelled with NITP and BrdUrd was carried out using the regions illustrated in Figure 1, Figure 6B ) before passing through mitosis. A proportion (10%) of BrdUrd-labelled cells appear to arrest permanently in G2 rather than progressing through mitosis.
DISCUSSION
Metabolic binding of NITP has a similar dependency on oxygen concentration to that of radiosensitivity (Hodgkiss et al, 1991) .
The K-value for binding (1400 p.p.m. oxygen) compared with the K-value (3800 p.p.m. oxygen) for radiosensitivity under identical conditions suggests that NITP binding requires slightly more stringent hypoxia than that needed for radioresistance. The majority of the NITP binding observed is therefore to relatively hypoxic radioresistant cells at oxygen tensions below the K-value for radiosensitivity. Tumours contain gradients of oxygen (and other nutrients) and the concept of hypoxic and well-oxygenated populations is an oversimplification. The population defined as hypoxic is probably heterogeneous in both the level and duration of low oxygen tensions to which the individual cells have been subjected. Some of the NITP binding may reflect different stringencies of hypoxia or, alternatively, may reflect acute variations in oxygen tension during the period of drug binding; it is not possible to distinguish between these alternatives at present.
British Journal of Cancer (1998) 77(2) (Moulder and Rockwell, 1984) . However, when some specific tumours were compared at different sizes, there was a trend for the hypoxic fraction to increase as size increased, although this was not true for all tumour types (Stanley et al, 1977; Siemann, 1980; Wallen et al, 1980; Okunieff et al, 1986; Fu et al, 1990) . Over the size range of 4-to 12-mm diameter, SaF, CaNT and Rh tumours showed no correlation between size and hypoxic fraction measured by flow cytometric analysis of bioreductively bound NITP abducts (Figure 2 ). The range in hypoxic fraction was large, even for tumours of similar diameter or weight. Inter-tumoral differences in hypoxic binding are not related to differences in drug (NITP) delivery Figure 3 and Table 2 ). Most of the cells in tumours tend to be in GI/Go and the predominance of G, cells in the hypoxic subpopulation probably reflects this. Cells are thought to arrest in GI as they move away from blood vessels, becoming hypoxic and nutritionally deprived (Tannock, 1968; Hirst and Denekamp, 1979) (Sutherland et al, 1986) . However, our observation of significant numbers of hypoxic S and G/M cells is also supported by other investigators (Pallavicini et al, 1979; Siemann and Keng, 1988) . Within each cell cycle phase (defined by DNA content) in SaF, CaNT and Rh tumours, the highest proportion of hypoxic cells was located within G2 ( Figure 4 and Table 3 ). Most in vitro cell cycle studies have shown that induction of hypoxia produces either total arrest of the cell cycle or cell cycle-specific arrest (Pettersen and Lindmo, 1983; Shrieve and Begg, 1985; Amellem and Pettersen, 1991) . Survival studies on different components of the cell cycle have shown S-phase to be the most sensitive to hypoxic treatment, with sensitivity slightly reduced in G1 and greatly reduced in G2 (Spiro et al, 1984) . Entry of cells into S is often blocked with an accumulation at the Ga/S border and cells can be either totally arrested in S such that no further DNA synthesis occurs, or progress slowly through S-phase with synthesis of DNA over a prolonged period (Pettersen and Lindmo, 1983) . Cells in G2/M have been reported to be insensitive to hypoxia, progressing through mitosis to Gp, where arrest may occur. In the in vivo studies presented here, a high proportion of hypoxic cells in G2 may have completed a hypoxic S-phase, perhaps with a reduced fidelity of DNA synthesis, and then progress slowly or are unable to continue through mitosis. Wilson et al (1994) reported that 20-25% of cells in untreated BrdUrd-labelled cells in SaF and Rh tumours arrested in G2 in the first cycle. Some of these G2 cells may no longer be clonogenic and may be committed to die from signals related to hypoxia or nutritional status.
Measurement of proliferation and hypoxia
Following BrdUrd-labelled cells through the cell cycle and assessing their hypoxia at time intervals showed that cells actively progressing through the cell cycle could become hypoxic ( Figure  5 ) and that their progression was delayed relative to the better oxygenated component. The hypoxic status of cells can only be determined at the time of labelling, and reoxygenation at other times can not be excluded and may account for some of the cell cycle progression. Slower progression of hypoxic compared with normoxic cells through G2 leads to a temporary accumulation of hypoxic G2 cells in CaNT tumours ( Figure 5B) and delays their entry into G, ( Figure 5A ). Similar but less marked trends are also observed in SaF tumours, in which progression of hypoxic cells appears to be relatively slow. In both tumour types a proportion of G2 cells became permanently arrested, and this appeared to be more closely related to oxygenation status in CaNT rather than in SaF tumours, in which other factors may be more important. It may be hypothesized that progression of the hypoxic cells in both tumour types is delayed because of deprivation of oxygen or other nutrients, but in these experiments chronically and acutely hypoxic cells can not be distinguished.
Labelling SaF tumours simultaneously with proliferation (BrdUrd) and hypoxia (NITP) markers and following the progress of this BrdUrd-labelled cohort through the cell cycle supported these observations (Figure 6 ). The presence of significant NITP binding 28 h after labelling demonstrated persistence of hypoxic cells in these tumours. Some progression through the cell cycle of these hypoxic S-phase cells was observed during this time. Slower progression of hypoxic compared with normoxic cells through G2 led to a temporary accumulation of hypoxic G2 cells 8 h after labelling ( Figure 6B ) and delayed their entry into G, ( Figure 6A ).
The observed delay in entry of hypoxic compared with oxic cells into G0 was much shorter after simultaneous compared with staggered administration of proliferation and hypoxia markers and may be evidence for reoxygenation of part of the hypoxic population during the time course of the experiment.
The G2 block seen after both staggered and simultaneous labelling with hypoxia and proliferation markers could reflect hypoxic S-phase DNA synthesis, which may increase the probability of faulty replication of DNA. p53 is induced by hypoxia and DNA damage and is responsible for cell cycle arrest in both G0 (Cox and Lane, 1995; Shimamura and Fisher, 1996) and G2 (Stewart et al, 1995) . A G2 delay would allow post-replication repair to occur, with sectoring of genetically damaged cells to undergo apoptosis or necrosis. A G2 block may also create a reservoir of pre-mitotic cells. In vitro modelling has shown that cells do not tend to enter DNA synthesis unless they have a good nutrient and oxygen supply. Gelfant (1977) also showed in vivo that mouse epithelium contained a number of cells permanently arrested in G2 that remained there for at least several months. These cells were activated when the tissue was injured to immediately repopulate the area through mitosis, while other cells initiated DNA synthesis. A reservoir of G2 cells in unfavourable (hypoxic) conditions could allow rapid repopulation if more favourable conditions within the tumour were restored.
In this study of cell cycle progression and hypoxia in vivo, evidence has been presented to show that hypoxic cells in tumours can not only actively synthesize DNA, but that some cell cycle progression is possible under hypoxic conditions, although at a slower rate than in better oxygenated cells. Hypoxic S-phase cells exhibit delayed progression through G2 into mitosis, and this may indicate a cell cycle checkpoint in G2 at which the fidelity of DNA synthesis in hypoxic or nutrient-deprived environments is monitored or DNA repair carried out. These studies demonstrate an approach towards elucidating the complex interactions between the hypoxic and proliferating compartments in tumours, which will help to identify the mechanisms involved in cell cycle regulation.
